,trastuzumab deruxtecan
astrazeneca,daiichi sankyo
['destiny04']
t-dxt destiny04 presentation gets an standing ovation in #asco22 and immediate change in practice with this drug. also a confirmation of the future of third generation adcs in oncology. 
Esposo, papá, Médico